Showing results (91-100 of 141) with videos related to
Sort By:
Pageof 15
Clinical and Experimental Immunology|August 12, 2009
Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel diseaseD C Baumgart, S Thomas, I Przesdzing, et al.Journal of Crohn'S & Colitis|January 29, 2016
Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim ResultsAxel Dignass, Ayesha Akbar, Ailsa Hart, et al.Inflammatory Bowel Diseases|July 6, 2022
Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis ProgramEdward V Loftus, Daniel C Baumgart, Krisztina Gecse, et al.Scientific Reports|September 3, 2024
Induction and maintenance of mucosal healing in Crohn's disease with ustekinumab in clinical practice across all care levels in Germany (MUCUS)Daniel C Baumgart, Andreas Stallmach, Philip Grunert, et al.Therapeutic Advances in Gastroenterology|March 1, 2024
Stricture dilation <i>via</i> balloon-assisted endoscopy in Crohn's disease: approach and intraprocedural outcomes with the single-balloon and double-balloon systemsBrendan P Halloran, Matthew Reeson, Christopher Teshima, et al.Transplant Immunology|January 6, 2024
Recruiting refugees and migrants as potential hematopoietic stem cell donors to serve patients of comparable ethnicities with rare human leucocyte antigen patterns - The BluStar.NRW project in North Western GermanyF M Heinemann, C Baumgart, C Binder, et al.Infection and Immunity|February 26, 2005
Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signalingAndreas Sturm, Klaus Rilling, Daniel C Baumgart, et al.Inflammatory Bowel Diseases|July 9, 2018
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative ColitisUma Mahadevan, Marla C Dubinsky, Chinyu Su, et al.Infection and Immunity|June 23, 2006
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathwaysA Grabig, D Paclik, C Guzy, et al.Gut|October 16, 2010
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitisWilliam J Sandborn, Jean Frederic Colombel, Matthew Frankel, et al.Pageof 15